Is Sermorelin Legal in Tennessee?

The Federal Legal Framework That Governs Sermorelin

Sermorelin's legality starts at the federal level, not the state level. Understanding what the FDA has and has not done with this peptide is the foundation of every downstream state-law question.

What Sermorelin Actually Is

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH 1-29). It stimulates the pituitary gland to release growth hormone through the same physiological pathway as native GHRH. The FDA originally approved a branded sermorelin product (Geref, Serono Laboratories) in 1997 for growth hormone deficiency in children, but that approval was voluntarily withdrawn by the manufacturer in 2008 for commercial, not safety, reasons. No safety-based recall ever occurred.

Because the branded product was withdrawn, sermorelin no longer has an active New Drug Application (NDA) on file. This places it in a regulatory space where it may be compounded under the rules of the Federal Food, Drug, and Cosmetic Act (FD&C Act) rather than dispensed as a commercial finished drug. [1]

FDA Compounding Rules: 503A vs. 503B

The FD&C Act, as amended by the Drug Quality and Security Act of 2013, creates two compounding pathways. [2]

503A pharmacies are traditional compounding pharmacies. They prepare patient-specific prescriptions and are regulated primarily by state boards of pharmacy. They may compound substances that are not on the FDA's "Category 1" (do-not-compound) bulk substances list and that are not copies of commercially available finished drugs. [2]

503B outsourcing facilities are larger-scale compounders that may produce batches without individual prescriptions. They register with the FDA and follow current Good Manufacturing Practice (cGMP) standards. [3]

Sermorelin does not appear on the FDA's published list of bulk drug substances that may not be used in compounding under section 503A. [4] The FDA has published a Category 1 list (substances that may not be compounded) and a separate list of substances under evaluation. As of January 2025, sermorelin has not been placed on the Category 1 prohibited list, meaning a licensed 503A pharmacy may compound it for a patient with a valid prescription. [4]

The FDA's position on peptides has shifted in recent years. In 2023 and 2024, the agency added several peptides to restricted lists (including BPC-157 and TB-500). Sermorelin has not been similarly restricted, though practitioners should verify current status at FDA.gov before prescribing. [4]

Schedule Status Under the Controlled Substances Act

Sermorelin is not a controlled substance under the Controlled Substances Act (CSA). [5] It is not listed in any DEA schedule (I through V). A prescriber does not need a DEA controlled-substance number to prescribe sermorelin, though standard state prescribing authority still applies.

Tennessee State Law and Sermorelin

Tennessee state law does not have a specific statute naming sermorelin. Instead, its legality under Tennessee law derives from several overlapping bodies of law: the Tennessee Food, Drug and Cosmetic Act, the Tennessee Board of Pharmacy regulations, the Tennessee Medical Practice Act, and the Tennessee Pharmacy Practice Act.

Tennessee Board of Pharmacy

The Tennessee Board of Pharmacy (TBOP) licenses all compounding pharmacies operating in Tennessee and enforces USP Chapter 795 (non-sterile) and USP Chapter 797 (sterile) compounding standards. [6] Sermorelin for injection is a sterile preparation and therefore falls under USP 797 requirements. A Tennessee-licensed 503A pharmacy that wants to dispense sermorelin must:

1. Hold a current Tennessee pharmacy permit.
2. Comply with USP 797 sterile compounding standards.
3. Receive a patient-specific prescription from a Tennessee-licensed (or out-of-state telehealth-permitted) prescriber.
4. Document clinical rationale supporting the prescription.

The TBOP does not maintain a separate "peptide prohibited" list. Compoundability under Tennessee law defaults to federal compounding law: if the FDA has not prohibited the substance, a properly licensed Tennessee pharmacy may prepare it. [6]

Tennessee Medical Practice Act and Prescribing Authority

Under Tennessee Code Annotated (TCA) Title 63, Chapter 6, licensed physicians (MD/DO) hold full prescribing authority for non-controlled substances including sermorelin. [7] Advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants (PAs) operating under a collaborative practice agreement may also prescribe sermorelin under TCA Title 63, Chapter 7. [7]

Off-label prescribing is explicitly lawful in Tennessee, as it is federally. The American Medical Association's Code of Medical Ethics states: "Physicians may prescribe drugs for off-label purposes when, in their judgment, available evidence supports their use." [8] Since sermorelin has no active FDA approval for adults, virtually all adult prescribing is technically off-label, but this does not make it illegal.

Telehealth Prescribing in Tennessee

Tennessee permits telehealth prescribing of non-controlled substances. Under TCA Title 63, Chapter 1, Section 155, a practitioner may establish a valid prescriber-patient relationship via synchronous audio-visual telehealth. [7] This means a Tennessee resident can receive a sermorelin prescription from a licensed telehealth provider (including out-of-state providers registered in Tennessee) without an in-person visit, provided:

• A real-time audio-visual encounter occurs.
• The prescriber reviews labs (typically IGF-1, IGFBP-3, and a basic metabolic panel).
• The prescription is transmitted to a licensed pharmacy.

Tennessee joined the Interstate Medical Licensure Compact (IMLC), making it straightforward for telehealth physicians licensed in multiple compact states to serve Tennessee patients legally. [9]

Clinical Background: Why Sermorelin Is Prescribed

Understanding why physicians prescribe sermorelin helps contextualize the legal question. A drug prescribed for no legitimate reason is more likely to attract regulatory scrutiny; sermorelin has documented clinical support.

Growth Hormone Deficiency in Adults

Adult growth hormone deficiency (AGHD) is a recognized endocrine condition associated with reduced lean body mass, increased visceral adiposity, reduced bone density, and impaired quality of life. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency recommends GH replacement when deficiency is biochemically confirmed. [10] Sermorelin stimulates endogenous GH release rather than supplying exogenous recombinant GH directly, which some clinicians consider advantageous because it preserves pituitary feedback regulation.

A randomized, double-blind, placebo-controlled trial by Walker et al. (N=89, 6 months) found that sermorelin acetate administered at 2 mg/day subcutaneously increased mean IGF-1 levels by 55% above baseline (P<0.01) compared to a 4% non-significant change in placebo. [11]

Age-Related GH Decline and Body Composition

GH secretion declines approximately 14% per decade after age 30, a process sometimes called somatopause. [12] Physiological GH decline contributes to age-related changes in body composition. A 26-week study by Corpas et al. (N=21 men aged 60-80) showed sermorelin administration increased mean 24-hour GH secretion by 88% above baseline and improved lean body mass by 1.4 kg (P<0.05). [11]

Diagnostic Work-Up Before Prescribing

Most responsible prescribers require lab confirmation before initiating sermorelin. A typical pre-prescription panel includes:

• IGF-1 (insulin-like growth factor 1): the primary biomarker for GH axis activity
• IGFBP-3 (IGF binding protein 3): adds sensitivity to GH deficiency screening
• Fasting glucose and HbA1c: sermorelin can transiently raise blood glucose [13]
• Thyroid panel (TSH, free T4): hypothyroidism blunts GH response to GHRH [10]
• Cortisol (morning): adrenal insufficiency must be ruled out before GH-axis stimulation

The Endocrine Society guideline notes: "Before initiating GH therapy, other pituitary hormone deficiencies should be evaluated and treated, as untreated hypothyroidism or hypocortisolism will prevent an adequate GH response." [10]

How to Get Sermorelin in Tennessee Legally

Getting sermorelin legally in Tennessee requires three things working together: a qualified prescriber, a valid prescription based on clinical assessment, and a licensed compounding pharmacy.

Step 1: Find a Qualified Prescriber

Options include:

• An endocrinologist or internist practicing in Tennessee. Endocrinologists have direct training in GH-axis disorders and are most likely to order a thorough work-up.
• An anti-aging or functional medicine physician licensed in Tennessee who is familiar with GHRH analogues.
• A telehealth provider registered to practice in Tennessee. Several telehealth platforms employ physicians licensed in Tennessee who routinely prescribe sermorelin after lab review.

The prescriber must hold an active Tennessee medical license (or an equivalent compact license recognized in Tennessee) and must conduct a clinical evaluation before issuing any prescription. [7]

Step 2: Get Appropriate Labs

The prescriber will typically order IGF-1 and IGFBP-3 at minimum. Some providers use a stimulation test (GHRH-arginine or insulin tolerance test) when AGHD is suspected. [10] Lab work can be drawn at a LabCorp, Quest Diagnostics, or hospital lab anywhere in Tennessee.

Step 3: Obtain the Prescription From a Licensed 503A Pharmacy

Once a prescription is written, it must be filled by a pharmacy that:

• Holds a current Tennessee Board of Pharmacy permit (or is licensed as an out-of-state pharmacy authorized to ship to Tennessee patients).
• Complies with USP 797 sterile compounding standards for injectable preparations. [6]
• Uses pharmaceutical-grade sermorelin acetate from an FDA-registered API supplier.

Common dispensed forms include lyophilized powder in 3 mg, 6 mg, or 9 mg multi-dose vials, reconstituted with bacteriostatic water for subcutaneous injection.

What Is Not Legal

Buying sermorelin from a research-chemical website without a prescription is illegal in Tennessee and federally. Under the FD&C Act, any drug (including compounded peptides) sold to humans without a valid prescription from a licensed practitioner constitutes misbranding and potentially unlawful dispensing. [1] Research-chemical vendors that label sermorelin "not for human use" to skirt FDA oversight are operating in a legally questionable gray area; purchasing from them carries personal legal and health risk. The FDA has issued multiple warning letters to such vendors. [4]

Self-injecting sermorelin purchased online without a prescription also bypasses the clinical safety checks (blood glucose monitoring, IGF-1 titration) that reduce risk.

Safety Profile and Monitoring

Sermorelin's safety profile is generally favorable compared to exogenous recombinant human GH (rhGH). Because it stimulates endogenous GH release rather than bypassing pituitary feedback, the risk of supraphysiological GH or IGF-1 levels is lower.

Known Adverse Effects

The most commonly reported adverse effects from clinical trials and post-marketing case series include:

• Injection site reactions (erythema, pain, swelling): reported in up to 17% of subjects in the original Geref trials. [11]
• Transient flushing and headache: mild, dose-dependent.
• Water retention and peripheral edema: particularly at doses above 1 mg/day.
• Transient hyperglycemia: sermorelin raises GH, which is counter-regulatory to insulin. Patients with pre-diabetes or diabetes require closer glucose monitoring. [13]

A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that GHRH analogues "demonstrate a more favorable side-effect profile than exogenous GH replacement, with a lower incidence of edema, arthralgia, and glucose dysregulation at equivalent IGF-1 endpoints." [12]

Contraindications

Absolute contraindications include active malignancy (GH-axis stimulation could theoretically promote tumor growth), pregnancy (no safety data), and known hypersensitivity to sermorelin acetate. [10] The Endocrine Society guideline states: "GH treatment is contraindicated in patients with active malignancy, intracranial hypertension, or proliferative diabetic retinopathy." [10] While that language addresses exogenous GH specifically, most practitioners apply the same caution to GHRH analogues.

Monitoring During Treatment

Standard monitoring includes IGF-1 measurement at 6 to 8 weeks after initiation, then every 3 to 6 months. The goal is an IGF-1 in the mid-normal range for age and sex, not the upper quartile. Fasting glucose should be checked at baseline and at 3 months. [13]

Sermorelin vs. Other GHRH Analogues: Legal Distinctions Matter

Sermorelin is often discussed alongside other GHRH analogues including CJC-1295, ipamorelin, and tesamorelin. Their legal statuses differ, and those differences are material in Tennessee as elsewhere.

Tesamorelin

Tesamorelin (brand name Egrifta) holds an active FDA approval for HIV-associated lipodystrophy. [3] As an FDA-approved drug, it may be dispensed as a finished pharmaceutical product. Compounding a copy of an FDA-approved drug is generally prohibited under 503A rules. [2]

CJC-1295 and Ipamorelin

CJC-1295 (a modified GHRH analogue) and ipamorelin (a ghrelin mimetic/GHRP) do not have FDA approval. The FDA placed ipamorelin on its list of bulk drug substances that may not be used in compounding under 503A in 2023. [4] CJC-1295's status remains under FDA review. Tennessee practitioners should not prescribe CJC-1295/ipamorelin combinations until the FDA completes its review, as dispensing a substance on the prohibited list violates federal law regardless of state rules. Sermorelin has not been added to this prohibited list. [4]

BPC-157 and TB-500

These peptides were added to the FDA 503A prohibited bulk substances list in 2023 and 2024, respectively. [4] They may not legally be compounded for human use at 503A pharmacies in Tennessee or any other state.

Sermorelin's continued absence from prohibited lists distinguishes it from these compounds and makes it the legally cleaner choice among GHRH-axis peptides currently available through compounding pharmacies.

Frequently Asked Questions